Cognition Therapeutics’ Founder/CSO to Provide Update on Elayta™ Clinical Progress at ADDF Alzheimer’s Drug Discovery Conference
PITTSBURGH, September 10, 2019 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative disorders, today announced that the company’s co-founder and chief science officer, Susan Catalano, Ph.D. will present an update on the Company’s lead candidate, Elayta™, at the 20th […]